-

11:43:45 AM

ONTX Stock News

ONTX - Onconova Therapeutics Inc

06/05/23 8:00 AM

Nasdaq : ONTX

Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting

Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a

RHEA-AI

neutral

05/25/23 8:00 AM

Nasdaq : ONTX

clinical trial

Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blockade

Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the first participant has been dosed in an

RHEA-AI

neutral

05/15/23 4:18 PM

Nasdaq : ONTX

earnings

Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced

RHEA-AI

neutral

05/12/23 8:00 AM

Nasdaq : ONTX

conferences

Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer

Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage

RHEA-AI

neutral

05/11/23 8:00 AM

Nasdaq : ONTX

clinical trial

Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer

Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage

RHEA-AI

neutral

05/08/23 8:00 AM

Nasdaq : ONTX

conferences

Onconova Therapeutics to Present at the ISID International Epidermolysis Bullosa Symposium

Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced an upcoming presentation at the

RHEA-AI

neutral

05/04/23 4:05 PM

Nasdaq : ONTX

earnings

Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023

Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel

RHEA-AI

neutral

04/19/23 9:00 AM

Nasdaq : ONTX

clinical trial

Onconova Therapeutics Announces the Presentation of New Preclinical Data on Narazaciclib at the AACR Annual Meeting

Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a

RHEA-AI

very positive

04/06/23 4:05 PM

Nasdaq : ONTX

Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark Gelder

Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that its Chief Medical Officer

RHEA-AI

neutral

03/23/23 8:00 AM

Nasdaq : ONTX

Onconova Therapeutics and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib

Collaboration builds off clinical data demonstrating rigosertib’s activity against PLK1 and may inform a precision medicine approach towards rigosertib’s evaluation in new indications Collaboration will leverage ENLIGHT, a pan-cancer response predictor scalable to all cancer types and all targeted

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next